Amicus Therapeutics Acquires Celenex for its Ten Gene Therapy Programs

 Amicus Therapeutics Acquires Celenex for its Ten Gene Therapy Programs

Amicus Therapeutics Acquires Celenex for its Ten Gene Therapy Programs

Shots:

  • Celenex (a Nationwide Children Hospital spin out) to receive an upfront of $100M cash, development milestones up to $15M, and may be eligible for up to $75M tiered sales ($500M /$750M) milestone payments with no royalties, $262M for BLA/MAA submission and approval milestones across multiple programs
  • Amicus will not pay >$75M over the next 4 years in these milestones. The acquisition and related development costs of the programs will be funded by Biopharma Credit PLC providing $150M debt facility
  • The lead programs in CLN6, CLN3, and CLN8 for Batten disease will support AAV vector developed by Nationwide Children Hospital in CNS genetic disease

Click here to read full press release/ article | Ref: Amicus Therapeutics | Image: Reuters

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post